ICUI vs TFX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ICUI · ICU Medical$172.11 ▲ 2.66%
TFX · Teleflex$150.87 ▼ 0.84%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ICUI +23.6%
- TFX +41.3%
Head to head
| Metric | ICUI | TFX |
|---|---|---|
| Price | $172.11 | $150.87 |
| Change today | ▲ 2.66% | ▼ 0.84% |
| Market cap | $4.30B | $5.98B |
| Return, 3 months | -5.7% | +13.7% |
| Return, year to date | +20.6% | +24.6% |
| Return, 1 year | +22.8% | +39.4% |
| P/E (TTM) | 72.0 | 19.9 |
| P/B | 2.0 | 1.7 |
| P/E percentile vs own 5y | 88th | 8th |
| Dividend yield | – | 0.90% |
| Revenue growth (YoY, latest qtr) | +0.5% | +28.9% |
| Net profit growth (YoY) | -46.0% | -18.7% |
| Gross margin | 39.1% | 54.9% |
| Operating margin | 6.7% | 8.3% |
| Net margin | 1.4% | -45.8% |
| Return on equity | 1.4% | -28.9% |
| Analyst target vs. price | +13.6% | +3.3% |
| Analyst buy share | 100% | 63% |
| RSI (14) | 59 | 76 |
| 30-day volatility | 34.8% | 31.1% |
| Max drawdown, 1 year | -27.2% | -24.1% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TFX is the largest of the group by market value.
- TFX has returned the most over the past year.
- TFX carries the lowest trailing P/E.
- TFX is growing revenue fastest.
- ICUI keeps the most profit per dollar of sales.
- TFX has been the calmest stock over the last 30 days.